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Milnacipran: recent findings in depression
Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) which was 
first approved for the treatment of major depressive episodes in France in December 
1996. It is currently marketed for this indication (as Ixel®, Toledomin®, Tivanyl® or 
Dalcipran®) in over 45 countries worldwide including Japan. It was approved for the 
management of fibromyalgia in the US in 2009.
This supplement, which is based on a symposium at the International Forum on 
Mood and Anxiety (IFMAD) held in Monaco in November 2009, highlights several 
recent clinical studies with milnacipran in depression.
The World Health Organization (WHO) classes suicide as one of the ten 
leading causes of death for all ages with more than 1.5 million deaths per year 
estimated for 2020.1 Reports of higher rates of suicide-related adverse events 
during treatment with selective serotonin reuptake inhibitors (SSRIs) and other 
antidepressants2 prompted regulatory bodies in the US and Europe to issue 
suicide risk warnings during the first weeks of antidepressant treatment. More 
recent evidence, however, suggests a   favorable benefit – risk ratio for treating 
depressed patients with antidepressants with the possible exception of those less 
than 25 years of age.3
In the first paper in this supplement, Philippe Courtet presents recent research on 
suicidal behavior and specifically a study of the effects of milnacipran on suicidal 
  behavior in depression patients. This study showed that suicidality decreased 
  progressively in parallel with other depressive symptoms and was essentially absent 
at the end of the study. At no time during treatment was there any increase of suicidal 
risk.
Depression is common in patients with diabetes and the co-morbidity has a seri-
ous negative impact on self-care, adherence to treatment and the general prognostic 
of diabetes. In particular co-morbid depression is associated with decreased metabolic 
control, a higher incidence of angiopathic complications and decreased quality of life 
for diabetes sufferers.4
In the second paper, Peter Hofmann discusses the treatment of co-morbid   depression 
in diabetes patients and in particular the question as to whether antidepressant   treatment 
can improve diabetes symptoms. SSRIs appear to treat the depression effectively 
but there is no evidence of any major effect on metabolic control. A recent study of 
milnacipran in diabetes patients with co-morbid depression showed, however, that a 
wide range of diabetes parameters were all significantly improved in patients with 
an antidepressant response but not in patients whose depressive symptoms had not 
responded to milnacipran.Neuropsychiatric Disease and Treatment
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Milnacipran and venlafaxine are both SNRIs but with 
differing selectivities for the two monoamines. Milnacipran 
has a balanced ratio of potency (1:1.16) for the inhibition 
of reuptake of the two neurotransmitters.5 One study has 
shown it to inhibit norepinephrine uptake with greater 
potency than serotonin (2.22:1).6 In contrast, venlafaxine 
has a 30-fold greater potency for the serotonin transporter 
than for the norepinephrine transporter.5 At low doses 
venlafaxine acts essentially as a SSRI, with significant 
noradrenergic activity occurring only at higher doses. Thus 
the choice of dose is critical for any meaningful comparison 
with venlafaxine.
In the third paper, Lucilla Mansuy discusses the various 
indirect comparisons that have been made between the 
two SNRIs. She then presents the first direct head-to-head 
comparison between venlafaxine and milnacipran with 
both drugs flexibly titrated to 150 to 200 mg/day and 
which shows the two SNRIs to have similar efficacy and 
tolerability.
In the fourth and final paper, Siegfried Kasper presents an 
updated overview of milnacipran in depression. He concludes 
that its distinct combination of favorable characteristics, 
namely its wide efficacy, good tolerability, low risk of 
pharmacokinetic drug – drug interactions, minimal, if any, 
sexual dysfunction or withdrawal effects, and safety in 
overdose, qualifies milnacipran as a first-line antidepressant 
treatment for any depressed patient. It may be particularly 
well-suited for low-energy, slowed-down patients.
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